Phaseline

Companies › Anhui Zhifei Longcom Biologic Pharmacy

Anhui Zhifei Longcom Biologic Pharmacy: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 4 Phase 1, 2 Phase 3, 1 Phase 4; Infectious disease, Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mycobacterium Vaccae for Injection
Live attenuated Mycobacterium vaccae vaccine
–Phase 4Latent Tuberculosis InfectionAug 2027
quadrivalent recombinant norovirus vaccine (Pichia pastoris)
Recombinant norovirus VP1 capsid proteins (GI.1, GII.3, GII.4, GII.17)
NOROVIRUSPhase 3Acute Gastroenteropathy Due to NorovirusMar 2027
BCG for Therapeutic Use
Live attenuated Mycobacterium bovis vaccine strain
–Phase 3BCGApr 2028
Recombinant herpes zoster vaccine (ZFA01 adjuvant, CHO cells) - Low-dose
Recombinant varicella-zoster virus glycoprotein E (50 μg) with ZFA01 adjuvant (375 μg)
–Phase 1Herpes ZosterMay 2029
BCG-PPD
BCG-PPD skin test antigen for tuberculosis diagnosis
–Phase 1Tuberculosis–
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant
Inactivated quadrivalent influenza vaccine with ZFA02 adjuvant
–Phase 1Influenza, Human–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04538911BCG-PPDPhase 1TuberculosisInfectious diseaseMay 2023
NCT06824519Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 AdjuvantPhase 1Influenza, HumanInfectious diseaseAug 2025
NCT06524947quadrivalent recombinant norovirus vaccine (Pichia pastoris)Phase 3Acute Gastroenteropathy Due to NorovirusInfectious diseaseMar 2027
NCT05680415Mycobacterium Vaccae for InjectionPhase 4Latent Tuberculosis InfectionInfectious diseaseAug 2027
NCT06747455BCG for Therapeutic UsePhase 3BCGOncologyApr 2028
NCT07920172Recombinant herpes zoster vaccine (ZFA01 adjuvant, CHO cells) - Low-dosePhase 1Herpes ZosterInfectious diseaseMay 2029
NCT07920172Recombinant herpes zoster vaccine (ZFA01 adjuvant, CHO cells) - Low-dosePhase 1Herpes ZosterInfectious diseaseMay 2029

Targets

NOROVIRUS (1)

Companies with the same targets

–

Companies built like this

Aimei Vacin BioPharm (Zhejiang) Institut Pasteur CanSino Biologics MAXVAX Biotechnology Limited Liability Company InventVacc Biologicals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.